Senvest Management LLC Grows Position in Illumina, Inc. (NASDAQ:ILMN)

Senvest Management LLC raised its position in Illumina, Inc. (NASDAQ:ILMN) by 19.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,070,292 shares of the life sciences company’s stock after acquiring an additional 174,532 shares during the period. Illumina makes up approximately 4.4% of Senvest Management LLC’s holdings, making the stock its 8th biggest holding. Senvest Management LLC owned 0.67% of Illumina worth $143,023,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the business. Versant Capital Management Inc increased its position in Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after buying an additional 146 shares in the last quarter. Golden State Wealth Management LLC purchased a new stake in shares of Illumina during the fourth quarter worth about $32,000. Assetmark Inc. increased its holdings in shares of Illumina by 954.8% during the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock valued at $44,000 after acquiring an additional 296 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich purchased a new position in shares of Illumina in the 4th quarter valued at approximately $45,000. Finally, Lee Danner & Bass Inc. acquired a new stake in Illumina in the 4th quarter worth approximately $48,000. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Price Performance

Illumina stock opened at $74.78 on Monday. The stock has a market capitalization of $11.85 billion, a P/E ratio of -9.74, a P/E/G ratio of 1.60 and a beta of 1.38. The company’s fifty day moving average price is $88.58 and its 200 day moving average price is $122.25. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. Illumina, Inc. has a 1 year low of $68.70 and a 1 year high of $156.66.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, equities research analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ILMN has been the subject of several research reports. Robert W. Baird lowered their price objective on shares of Illumina from $127.00 to $90.00 and set a “neutral” rating for the company in a research note on Wednesday, March 5th. Royal Bank of Canada cut their price objective on Illumina from $128.00 to $112.00 and set an “outperform” rating on the stock in a report on Tuesday, April 8th. Hsbc Global Res downgraded Illumina from a “strong-buy” rating to a “hold” rating in a report on Friday, February 28th. Barclays cut their price target on shares of Illumina from $100.00 to $77.00 and set an “underweight” rating on the stock in a report on Thursday. Finally, Guggenheim decreased their price objective on shares of Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a research note on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $138.70.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.